4ub0
From Proteopedia
New design for monovalent bispecific IgG through cysteine engineering of the CH1-CL interface
Structural highlights
Publication Abstract from PubMedMonovalent bispecific IgGs cater to a distinct set of mechanisms of action but are difficult to engineer and manufacture because of complexities associated with correct heavy and light chain pairing. We have created a novel design, "DuetMab," for efficient production of these molecules. The platform uses knobs-into-holes (KIH) technology for heterodimerization of 2 distinct heavy chains and increases the efficiency of cognate heavy and light chain pairing by replacing the native disulfide bond in one of the CH1-CL interfaces with an engineered disulfide bond. Using two pairs of antibodies, cetuximab (anti-EGFR) and trastuzumab (anti-HER2), and anti-CD40 and anti-CD70 antibodies, we demonstrate that DuetMab antibodies can be produced in a highly purified and active form, and show for the first time that monovalent bispecific IgGs can concurrently bind both antigens on the same cell. This last property compensates for the loss of avidity brought about by monovalency and improves selectivity toward the target cell. Improving target cell specificity using a novel monovalent bispecific IgG design.,Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenmeier K, Carlson M, Gadre DV, Borrok MJ, Yu XQ, Dall'Acqua W, Wu H, Chowdhury PS MAbs. 2015;7(2):377-89. doi: 10.1080/19420862.2015.1007816. PMID:25621507[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|